NFKBとJAK-STAT経路を阻害することによって,シナージ的内皮炎を標的とする
Stijn A Groten1, Pieter Langerhorst1, Georgios Malamas1
1Department of Molecular Hematology, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands.
iScience
|September 2, 2025
まとめ
NFKBとJAK/STAT経路をターゲットにすることで,血管疾患における内皮炎症を減らすことができます. 阻害剤は,TNFαとIFNγの刺激によって誘発された主要な炎症反応と細胞外フォン・ウィレブランド因子ネットワークを阻害した.
科学分野:
- 血管生物学
- 免疫学
- 細胞生物学
背景:
- システム血管炎症症は内皮機能障害を伴う.
- 腫瘍死因アルファ (TNFα) とインターフェロンガンマ (IFNγ) は,NFKBとJAK/ STAT経路を通じて内皮細胞 (ECs) の高炎症を相乗的に促進する.
研究 の 目的:
- EC炎症に対するNFKBとJAK/STAT経路の標的化効果を調査する.
- TNFαとIFNγで刺激されたECFCの全システムにわたるタンパク質変化を理解する.
主な方法:
- 質量スペクトロメトリーベースのプロテオミクスを利用して,内皮コロニー形成細胞 (ECFC) を分析した.
- NFKB (IKK2 / STAT3 阻害剤 TPCA1) と JAK / STAT (JAK1 阻害剤 イタシチニブ) 経路を標的とした適用された阻害剤.
- ピロプトーシスメディエーターとケモカインを含むタンパク質発現の変化を調べ,フォン・ウィレブランド因子 (VWF) ネットワークを視覚化した.
主要な成果:
- JAK1阻害剤イタシチニブはIFNγ誘発のタンパク質変化を選択的に阻害し,TPCA1はTNFαとIFNγの両方に反応を弱めた.
- 両方の阻害剤はTNFα+IFNγ誘発タンパク質のほとんどを効果的に抑制し,両経路の相乗効果を示した.
- 結合刺激により,細胞外VWFネットワークが形成され,このVWFネットワークは両方の阻害剤によって逆転した.
結論:
- TNFαとIFNγを組み合わせた刺激は,NFKBとJAK/STAT経路の両方に依存するシネージ的内皮炎を引き起こします.
- イタシチニブやTPCA1のような阻害剤でこれらの経路を標的にすると,ECにおける主要な炎症現象を逆転させることができます.
- この研究は,血管疾患における内皮炎に対する治療戦略を開発するための基盤を提供します.
関連する概念動画
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K


